Carol A Langford

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Wegener granulomatosis
    C A Langford
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med Sci 321:76-82. 2001
  2. ncbi Wegener's granulomatosis: current and upcoming therapies
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Arthritis Res Ther 5:180-91. 2003
  3. ncbi Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med 114:463-9. 2003
  4. ncbi Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    Arthritis Rheum 51:278-83. 2004
  5. ncbi Biologic therapies in the vasculitides
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 15:3-10. 2003
  6. ncbi Pregnancy in vasculitis
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 14:36-41. 2002
  7. ncbi Treatment of ANCA-associated vasculitis
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 349:3-4. 2003
  8. ncbi New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney
    Carol A Langford
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-1818, USA
    Curr Opin Nephrol Hypertens 12:267-72. 2003
  9. ncbi CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis
    Ronald M Summers
    Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1182, USA
    Chest 121:242-50. 2002
  10. ncbi Tarsal-conjunctival disease associated with Wegener's granulomatosis
    Michael R Robinson
    National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ophthalmology 110:1770-80. 2003

Detail Information

Publications23

  1. ncbi Wegener granulomatosis
    C A Langford
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med Sci 321:76-82. 2001
    ..Although drug toxicity and disease relapse remain of concern with this regimen, it has provided us with a successful means of treatment and the opportunity to better understand this disease through long-term patient follow-up...
  2. ncbi Wegener's granulomatosis: current and upcoming therapies
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Arthritis Res Ther 5:180-91. 2003
    ..Careful study of new agents through rigorously designed trials is essential to answering questions of safety and efficacy in Wegener's granulomatosis...
  3. ncbi Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med 114:463-9. 2003
    ..To determine the relapse rate and outcome in patients with Wegener's granulomatosis treated with daily cyclophosphamide and glucocorticoids to induce remission followed by methotrexate for remission maintenance...
  4. ncbi Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
    Carol A Langford
    National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    Arthritis Rheum 51:278-83. 2004
    ..To examine the safety of mycophenolate mofetil (MMF) for remission maintenance in patients with Wegener's granulomatosis (WG) who had been treated with daily cyclophosphamide (CYC) and glucocorticoids to induce remission...
  5. ncbi Biologic therapies in the vasculitides
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 15:3-10. 2003
    ..In the research setting, investigation of biologic agents in the treatment of vasculitic diseases may also provide important insights into pathogenesis of these syndromes...
  6. ncbi Pregnancy in vasculitis
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Rheumatol 14:36-41. 2002
    ..Maternal and fetal outcome is optimized by the establishment of a multidisciplinary team that can provide preconception evaluation and counseling followed by frequent monitoring throughout the pregnancy and the postpartum period...
  7. ncbi Treatment of ANCA-associated vasculitis
    Carol A Langford
    Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 349:3-4. 2003
  8. ncbi New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney
    Carol A Langford
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-1818, USA
    Curr Opin Nephrol Hypertens 12:267-72. 2003
    ....
  9. ncbi CT virtual bronchoscopy of the central airways in patients with Wegener's granulomatosis
    Ronald M Summers
    Diagnostic Radiology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1182, USA
    Chest 121:242-50. 2002
    ..To compare CT virtual bronchoscopy (VB) to CT alone and to conventional bronchoscopy for evaluation of central airway stenoses in patients with Wegener's granulomatosis...
  10. ncbi Tarsal-conjunctival disease associated with Wegener's granulomatosis
    Michael R Robinson
    National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ophthalmology 110:1770-80. 2003
    ..To describe the clinical characteristics of tarsal-conjunctival disease in a cohort of patients with Wegener's granulomatosis (WG)...
  11. ncbi A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis
    Michael C Sneller
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20854, USA
    Arthritis Rheum 64:835-42. 2012
    ..To perform a randomized controlled trial of rituximab in patients with hepatitis C virus (HCV)-associated mixed cryoglobulinemic vasculitis...
  12. ncbi 15. Vasculitis
    Carol A Langford
    Immunologic Diseases Section, National Institute of Allergy and Infectious Diseases/NIH, Building 10, Room 11B-13, Bethesda, MD 20892, USA
    J Allergy Clin Immunol 111:S602-12. 2003
    ..Recent investigations have focused on understanding the pathophysiology of these diseases, which may lead to more efficacious and less toxic therapeutic options...
  13. ncbi The future of damage assessment in vasculitis
    Philip Seo
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 34:1357-71. 2007
    ..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides...
  14. ncbi Update on Wegener granulomatosis
    Carol A Langford
    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 72:689-90, 693-7. 2005
    ..Current treatments induce remission and allow long-term survival...
  15. ncbi Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases
    Carol A Langford
    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases at Cleveland Clinic, Cleveland, OH 44195, USA
    Nat Clin Pract Rheumatol 4:364-70. 2008
    ..Caution is necessary in clinical practice until such data become available...
  16. ncbi Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience
    Alexandra Villa Forte
    Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Medicine (Baltimore) 86:269-77. 2007
    ..However, relapses were common and incremental permanent morbidity occurred in most patients. While not a goal of therapy, when treatment produced marked lymphopenia, prolonged remissions were more likely...
  17. ncbi Are there different forms of life in the antineutrophil cytoplasmic antibody universe?
    Gary S Hoffman
    Ann Intern Med 143:683-5. 2005
  18. ncbi How can relapses be detected and prevented in primary systemic small-vessel vasculitides?
    Carol A Langford
    Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, 9500 Euclid Avenue, A50, Cleveland, OH 44195, USA
    Best Pract Res Clin Rheumatol 19:307-20. 2005
    ..Recent clinical trials have sought to investigate safer therapeutic options that decrease disease relapse...
  19. ncbi Vasculitis in the geriatric population
    Carol A Langford
    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, 9500 Euclid Avenue, A50, Cleveland, OH 44195, USA
    Rheum Dis Clin North Am 33:177-95. 2007
    ..A thorough understanding of the vasculitic disease entities that may affect older patients as well as their diagnosis and management is essential in minimizing disease and treatment-related morbidity and mortality...
  20. ncbi Vasculitis in the geriatric population
    Carol A Langford
    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Geriatr Med 21:631-47, viii. 2005
    ..A thorough understanding of the vasculitic disease entities that may affect older patients as well as their diagnosis and management is essential in minimizing disease and treatment related morbidity and mortality...
  21. ncbi Novel therapeutic strategies for large vessel vasculitis
    Curry L Koening
    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Rheum Dis Clin North Am 32:173-86, xi. 2006
    ..This limitation has lead to the investigation of alternative agents for the treatment of these diseases...
  22. ncbi Vasculitis mimics
    Eamonn S Molloy
    Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Ohio 44195, USA
    Curr Opin Rheumatol 20:29-34. 2008
    ..There are many disorders that may closely resemble the clinical, radiologic and/or pathologic features of the primary vasculitides. In this review, we focus on recently described and under-recognized syndromes that may mimic vasculitis...
  23. ncbi Intravenous immunoglobulin in Wegener's granulomatosis and microscopic polyangiitis
    Carol A Langford
    Arthritis Rheum 58:2211-2; author reply 2212. 2008